Jagsonpal Pharmaceuticals Ltd vs Sun Pharmaceutical Industries Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Jagsonpal Pharmaceuticals Ltd is ₹ 210.3 as of 30 Apr 15:30 . The P/E Ratio of Jagsonpal Pharmaceuticals Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Sun Pharmaceutical Industries Ltd changed from 49.4 on March 2021 to 38.1 on March 2025 . This represents a CAGR of -5.06% over 5 years The Market Cap of Jagsonpal Pharmaceuticals Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Sun Pharmaceutical Industries Ltd changed from ₹ 143384 crore on March 2021 to ₹ 416392 crore on March 2025 . This represents a CAGR of 23.77% over 5 years The revenue of Jagsonpal Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Sun Pharmaceutical Industries Ltd for the Dec '25 is ₹ 16099 crore as compare to the Sep '25 revenue of ₹ 14948 crore. This represent the growth of 7.7% The ebitda of Jagsonpal Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Sun Pharmaceutical Industries Ltd for the Dec '25 is ₹ 5037 crore as compare to the Sep '25 ebitda of ₹ 4996 crore. This represent the growth of 0.82% The net profit of Jagsonpal Pharmaceuticals Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Sun Pharmaceutical Industries Ltd changed from ₹ 2871 crore to ₹ 3401 crore over 7 quarters. This represents a CAGR of 10.16% The Dividend Payout of Jagsonpal Pharmaceuticals Ltd changed from 15.36 % on March 2021 to 29.99 % on March 2025 . This represents a CAGR of 14.32% over 5 yearsThe Dividend Payout of Sun Pharmaceutical Industries Ltd changed from 213.61 % on March 2021 to 89.64 % on March 2025 . This represents a CAGR of -15.94% over 5 years .

About Jagsonpal Pharmaceuticals Ltd

Promoted by Rajpal Singh Kochhar in August, 1978, Jagsonpal Pharmaceuticals Limited is engaged in the manufacture and marketing bulk drugs and pharmaceuticals at its plant at Faridabad in Haryana.
The Company has adopted the strategy of clubbing all its products in seven groups for effective marketing and reducing costs.
Simultaneously, it has geared up to set up an ultra modern multi-purpose basic drugs and formulation plant through its subsidiary, Jagsonpal Exports India Pvt Ltd. The company has a strategic alliance with Fidia Spa, Italy; and B Spofola, Czechoslovakia; to manufacture sophisticated drugs in India.
It has tied up with another Israel-based company, Makhteshim Chemical Works, for acquiring the marketing rights of an anti-oxidant product.
In 1994, the company has also promoted Aresco Financial Services, a new financial company.

About Sun Pharmaceutical Industries Ltd

Sun Pharmaceutical Industries Limited including its subsidiaries and associates is the fourth largest global specialty generic company that is ranked No. 1 in India and No. 8 in the US. It is the largest Indian pharmaceutical company in the US and among the leading Indian pharmaceutical companies in emerging markets.
The company manufactures and markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies.
It includes generics, branded generics, complex or difficult to make technology intensive products, over-the-counter (OTC) products, anti-retrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and intermediates.
The product portfolio of over 2000 high quality molecules covers multiple dosage forms, including tablets, capsules, injectables, sprays, inhalers, drug delivery systems, ointments, creams and liquids.

FAQs for the comparison of Jagsonpal Pharmaceuticals Ltd and Sun Pharmaceutical Industries Ltd

Which company has a larger market capitalization, Jagsonpal Pharmaceuticals Ltd or Sun Pharmaceutical Industries Ltd?

Market cap of Jagsonpal Pharmaceuticals Ltd is 1,411 Cr while Market cap of Sun Pharmaceutical Industries Ltd is 433,847 Cr

What are the key factors driving the stock performance of Jagsonpal Pharmaceuticals Ltd and Sun Pharmaceutical Industries Ltd?

The stock performance of Jagsonpal Pharmaceuticals Ltd and Sun Pharmaceutical Industries Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Jagsonpal Pharmaceuticals Ltd and Sun Pharmaceutical Industries Ltd?

As of May 4, 2026, the Jagsonpal Pharmaceuticals Ltd stock price is INR ₹210.3. On the other hand, Sun Pharmaceutical Industries Ltd stock price is INR ₹1808.2.

How do dividend payouts of Jagsonpal Pharmaceuticals Ltd and Sun Pharmaceutical Industries Ltd compare?

To compare the dividend payouts of Jagsonpal Pharmaceuticals Ltd and Sun Pharmaceutical Industries Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.